Filing Details
- Accession Number:
- 0001144204-11-033017
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-05-27 18:12:43
- Reporting Period:
- 2011-05-25
- Filing Date:
- 2011-05-27
- Accepted Time:
- 2011-05-27 18:12:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1326190 | Pharmathene Inc | PIP | Pharmaceutical Preparations (2834) | 202726770 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
897464 | John Pappajohn | C/O Pharmathene, Inc., One Park Place, Suite 450 Annapolis MD 21401 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, $0.0001 Par Value Per Share | Disposition | 2011-05-25 | 50,000 | $3.68 | 394,044 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnote |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock, $0.0001 Par Value Per Share | 911,164 | Direct |
Footnotes
- The shares reported in this row are owned by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of such shares, and this report shall not be deemed an admission that the reporting person was or is the beneficial owner of the shares for purposes of Section 13(d) or Section 16 of the Exchange Act or for any other purpose.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.73, inclusive. The reporting person undertakes to provide to PharmAthene, Inc., any security holder of PharmAthene, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.